SOUTH SAN FRANCISCO, Calif. – Sept. 11, 2018 – As part of their Series C financing, Biodesy has dedicated funds to expanding commercial efforts. Over the last four months the company has partnered with United BioChannels, a life science brand management company, to explore applications and customer needs, and to refine Biodesy’s value proposition and messaging. To increase access to Biodesy’s novel technology to detect structural changes in biological molecules and the Delta™ System, Biodesy will further grow its fee-for-service engagement efforts. In partnership with United BioChannels, Biodesy will expand reach in North America and Europe to increase industry adoption of the technology. For more information, please email email@example.com.
About United BioChannels
United BioChannels (UBC) is a life science brand management company providing full-service sales and marketing that de-risks the commercial process for companies and their investors. For more information, please visit www.unitedbiochannels.com.
Biodesy is a next-generation biomolecule characterization company focused on catalyzing the discovery and development of novel therapeutics for human disease. The company’s Delta™ System and core Second Harmonic Generation (SHG) technology enables researchers to monitor structural changes in real time and high throughput for the first time, and it has been successfully applied to over 80 different targets representing more than 15 different target classes. The company has placed instruments at multiple biopharmaceutical and academic sites and is partnering with leading pharmaceutical and biotechnology companies to gain significant insights into how different biomolecules function and respond to drug candidates. Biodesy is located in South San Francisco, California. For more information, please visit www.biodesy.com.
The Biodesy Delta System is for Research Use Only and not for use in diagnostic procedures.
Biodesy, the Biodesy logo and Delta System are trademarks of Biodesy, Inc. All other brands may be trademarks of their respective holders.